Bio-Rad Laboratories vs Spyre Therapeutics

Bio-Rad Laboratories (BIO), health care, and Spyre Therapeutics (SYRE), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bio-Rad Laboratories is worth $9.6B on the stock market and Spyre Therapeutics $8.9B: Bio-Rad Laboratories is valued at 8% more. Over the past year Bio-Rad Laboratories's share price has moved +17.1% and Spyre Therapeutics's +312%.

Key facts

Bio-Rad Laboratories market value
$9.6B
Spyre Therapeutics market value
$8.9B
Bio-Rad Laboratories P/E
9.6
Bio-Rad Laboratories revenue
$2.6BFY to 2025-12-31
Spyre Therapeutics revenue
$0FY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Bio-Rad Laboratories vs Spyre Therapeutics: every measure side by side
Measure Bio-Rad Laboratories Spyre Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$9.6Bhigher$8.9Blower
Revenue$2.6Bhigher$0lower
Earnings$759.9Mhigher-$155.2Mlower
Employees7,450higher130lower
Total assets$10.6Bhigher$777.8Mlower
Valuation
P/E9.6—
P/S3.7—
P/B1.3lower9.3higher
Dividend yield0.00%0.00%
Profitability
Operating margin1.83%—
Balance sheet
Net assets$7.5Bhigher$715.2Mlower
Total liabilities$3.1Bhigher$62.5Mlower
Total debt$1.2B—
Cash on hand$529.8Mhigher$85.7Mlower
Price change
Today-0.57%higher-5.60%lower
1 year+17.1%lower+312%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Bio-Rad Laboratories only (3)

Spyre Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns BIO · Who owns SYRE

Further comparisons

Learn

Questions and answers

Which is bigger, Bio-Rad Laboratories or Spyre Therapeutics?

By market value, Bio-Rad Laboratories is the larger: $9.6B against $8.9B for Spyre Therapeutics. By revenue in its latest fiscal year, Bio-Rad Laboratories is the larger: $2.6B against $0 for Spyre Therapeutics.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Bio-Rad Laboratories and Spyre Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Bio-Rad Laboratories and 1 holds Spyre Therapeutics.

Cite this page

Funkfolio, “Bio-Rad Laboratories vs Spyre Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/bio-vs-syre

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.